CR20230182A - MODULADORES DE PROFÁRMACOS DE LA VÍA DE ESTRÉS INTEGRADA (Divisional Expediente 2021-238) - Google Patents

MODULADORES DE PROFÁRMACOS DE LA VÍA DE ESTRÉS INTEGRADA (Divisional Expediente 2021-238)

Info

Publication number
CR20230182A
CR20230182A CR20230182A CR20230182A CR20230182A CR 20230182 A CR20230182 A CR 20230182A CR 20230182 A CR20230182 A CR 20230182A CR 20230182 A CR20230182 A CR 20230182A CR 20230182 A CR20230182 A CR 20230182A
Authority
CR
Costa Rica
Prior art keywords
prodrug
modulators
integrated stress
stress pathway
integrated
Prior art date
Application number
CR20230182A
Other languages
English (en)
Inventor
Marina Pliushchev
Kathleen Ann Martin
Jennifer M Frost
Michael J Dart
Lei Shi
Xiangdong Xu
Kathleen Murauski
Eric Voight
Carmela Sidrauski
Brian S Brown
Yunsong Tong
John T Randolph
Original Assignee
Calico Life Sciences Llc
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc, Abbvie Inc filed Critical Calico Life Sciences Llc
Publication of CR20230182A publication Critical patent/CR20230182A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/34—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/20—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos de utilidad para modular la respuesta al estrés integrada (ISR) y para tratar enfermedades, trastornos y condiciones relacionados.
CR20230182A 2018-10-11 2019-10-11 MODULADORES DE PROFÁRMACOS DE LA VÍA DE ESTRÉS INTEGRADA (Divisional Expediente 2021-238) CR20230182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744293P 2018-10-11 2018-10-11
PCT/US2019/055850 WO2020077217A1 (en) 2018-10-11 2019-10-11 Prodrug modulators of the integrated stress pathway

Publications (1)

Publication Number Publication Date
CR20230182A true CR20230182A (es) 2023-06-14

Family

ID=68387427

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230182A CR20230182A (es) 2018-10-11 2019-10-11 MODULADORES DE PROFÁRMACOS DE LA VÍA DE ESTRÉS INTEGRADA (Divisional Expediente 2021-238)

Country Status (35)

Country Link
US (2) US11149043B2 (es)
EP (3) EP4209483B1 (es)
JP (3) JP7203964B2 (es)
KR (3) KR20220151232A (es)
CN (2) CN116283647A (es)
AR (2) AR116693A1 (es)
AU (2) AU2019356565B2 (es)
CA (1) CA3115668A1 (es)
CL (1) CL2021000875A1 (es)
CO (1) CO2021006098A2 (es)
CR (1) CR20230182A (es)
DK (1) DK3864003T3 (es)
DO (1) DOP2021000064A (es)
EC (1) ECSP21032861A (es)
ES (1) ES2938061T3 (es)
FI (1) FI3864003T3 (es)
HR (1) HRP20230222T1 (es)
HU (1) HUE061297T2 (es)
IL (3) IL300799B2 (es)
LT (1) LT3864003T (es)
MA (1) MA53861B1 (es)
MD (1) MD3864003T2 (es)
MX (2) MX2021004163A (es)
MY (1) MY207223A (es)
PE (2) PE20211277A1 (es)
PH (1) PH12021550786A1 (es)
PL (1) PL3864003T3 (es)
PT (1) PT3864003T (es)
RS (1) RS64013B1 (es)
SG (1) SG11202103531YA (es)
SI (1) SI3864003T1 (es)
SM (1) SMT202300058T1 (es)
TW (4) TWI771621B (es)
UY (1) UY38415A (es)
WO (1) WO2020077217A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200054A (es) 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
HUE062446T2 (hu) 2017-09-01 2023-11-28 Denali Therapeutics Inc Vegyületek, készítmények és eljárások
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
AU2018383675A1 (en) 2017-12-13 2020-07-09 Altos Labs, Inc. Inhibitors of integrated stress response pathway
MX2020013269A (es) 2018-06-05 2021-02-18 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
TWI771621B (zh) * 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3923935A4 (en) 2019-02-13 2022-10-26 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
CN114466654A (zh) 2019-06-12 2022-05-10 普拉西斯生物技术有限责任公司 整合应激反应通路调节剂
CA3165813A1 (en) 2020-03-11 2021-09-16 Holly Victoria Atton Modulators of the integrated stress response pathway
KR20230110509A (ko) 2020-10-22 2023-07-24 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
MX2023004626A (es) 2020-10-22 2023-05-23 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
AU2021363616B2 (en) 2020-10-22 2026-03-26 Evotec International Gmbh Modulators of the integrated stress response pathway
KR102899421B1 (ko) 2020-11-13 2025-12-12 고쿠리츠 다이가꾸 호우진 시즈오까 다이가꾸 방사선 촬상 장치
EP4268818A4 (en) * 2020-12-25 2024-06-19 Shanghai Shengdi Pharmaceutical Co., Ltd USE OF AN NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH A 5-HT3 RECEPTOR ANTAGONIST
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11993577B2 (en) 2021-09-01 2024-05-28 Empathbio, Inc. Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers
WO2023056102A1 (en) 2021-10-01 2023-04-06 ATAI Life Sciences AG Novel prodrugs of mdma, mda, and derivatives thereof
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CN118141794A (zh) * 2024-01-24 2024-06-07 同济大学 ISR抑制剂ISRIB在制备治疗Wolfram综合征的药物中的应用
WO2025230528A1 (en) * 2024-05-01 2025-11-06 Calico Life Sciences Llc Methods of treating amyotrophic lateral sclerosis

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US162A (en) 1837-04-17 Island
US5212A (en) 1847-07-31 Richard m
GB1026506A (en) 1962-10-17 1966-04-20 Du Pont Bicyclodiamines and preparation thereof
US3264351A (en) 1964-07-08 1966-08-02 American Home Prod 1, 4-diaminobicyclo [2.2.2] octanes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPH02215779A (ja) 1989-02-14 1990-08-28 Kuraray Co Ltd カルボン酸アミド誘導体類及びその医薬用途
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
JPH09500133A (ja) 1993-07-16 1997-01-07 メルク エンド カンパニー インコーポレーテッド オキシトシンのアンタゴニストである置換ピペラジニル樟脳誘導体
US6919343B2 (en) 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
WO2003065789A2 (en) 2002-02-08 2003-08-14 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CA2517034A1 (en) * 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
WO2005077900A1 (ja) 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. ビシクロアミド誘導体
KR101302627B1 (ko) 2005-01-05 2013-09-10 아비에 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
US20100029615A1 (en) 2006-12-15 2010-02-04 Michael John Munchhof Benzimidazole derivatives
CA2735420C (en) 2008-09-08 2016-06-28 Merck Patent Gmbh Macrocyclic pyrimidines as protein kinase inhibitors
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
WO2011087758A1 (en) 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
AR084457A1 (es) 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
JPWO2013161980A1 (ja) 2012-04-27 2015-12-24 東レ株式会社 シクロヘキサンジアミド誘導体及びその医薬用途
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
US9580459B2 (en) 2013-04-26 2017-02-28 Metselex, Inc. Water-soluble ursodeoxycholic acid prodrugs
US20160318856A1 (en) 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators
RU2016141934A (ru) 2014-04-04 2018-05-07 Сирос Фармасьютикалз, Инк. Ингибиторы циклин-зависимой киназы 7 (cdk7)
US20150362847A1 (en) 2014-06-13 2015-12-17 Canon Kabushiki Kaisha Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
MX2017014222A (es) 2015-05-05 2018-08-15 Bayer Pharma AG Derivados de ciclohexano sustituido con amido.
WO2017040606A1 (en) 2015-08-31 2017-03-09 Proteostasis Therapeutics, Inc. Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders
TW201722958A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
KR20190015748A (ko) 2016-06-08 2019-02-14 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Atf4 경로 억제제로서의 화학적 화합물
JP7049276B2 (ja) 2016-06-24 2022-04-06 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピンおよびその結合体
CN106349130B (zh) 2016-08-25 2018-01-23 潍坊大有生物化工有限公司 一种新的氟苯尼考的合成方法
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
CR20200054A (es) 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
AU2018317346B2 (en) * 2017-08-14 2021-08-26 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
HUE062446T2 (hu) 2017-09-01 2023-11-28 Denali Therapeutics Inc Vegyületek, készítmények és eljárások
AU2018358157B2 (en) 2017-11-02 2023-03-09 Abbvie Inc. Modulators of the integrated stress pathway
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090078A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
EP3704089B1 (en) 2017-11-02 2023-07-19 Calico Life Sciences LLC Modulators of the integrated stress pathway
CA3080948A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3768660A1 (en) 2018-03-23 2021-01-27 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
CN108517001A (zh) 2018-05-17 2018-09-11 江苏恩华络康药物研发有限公司 水溶性别孕烯醇酮衍生物及其用途
EP3820843A1 (en) 2018-07-09 2021-05-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
TWI771621B (zh) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3962899A1 (en) 2019-04-30 2022-03-09 Calico Life Sciences LLC Substituted cyclolakyls as modulators of the integrated stress pathway
PE20220572A1 (es) 2019-04-30 2022-04-20 Calico Life Sciences Llc Moduladores de la via integrada del estres

Also Published As

Publication number Publication date
MX2021004163A (es) 2021-06-08
KR102464077B1 (ko) 2022-11-10
TW202325692A (zh) 2023-07-01
AU2024200013A1 (en) 2024-01-25
ECSP21032861A (es) 2021-06-30
MD3864003T2 (ro) 2023-09-30
EP4714961A2 (en) 2026-03-25
IL300799A (en) 2023-04-01
IL282153B1 (en) 2023-03-01
KR20220151232A (ko) 2022-11-14
TW202028173A (zh) 2020-08-01
WO2020077217A1 (en) 2020-04-16
MY207223A (en) 2025-02-06
IL321549A (en) 2025-08-01
CL2021000875A1 (es) 2021-10-29
EP3864003B1 (en) 2022-12-07
MX2023009561A (es) 2023-08-22
BR122023020960A2 (pt) 2024-01-09
AU2019356565B2 (en) 2023-10-05
US20220251123A1 (en) 2022-08-11
PT3864003T (pt) 2023-02-08
JP2023040106A (ja) 2023-03-22
KR20250153325A (ko) 2025-10-24
PL3864003T3 (pl) 2023-05-29
PE20241068A1 (es) 2024-05-13
KR20210075139A (ko) 2021-06-22
JP7203964B2 (ja) 2023-01-13
CN116283647A (zh) 2023-06-23
IL282153A (en) 2021-05-31
MA53861A (fr) 2021-08-18
PE20211277A1 (es) 2021-07-19
TWI877863B (zh) 2025-03-21
AR116693A1 (es) 2021-06-02
SG11202103531YA (en) 2021-05-28
AU2024200013B2 (en) 2026-04-02
JP2022504638A (ja) 2022-01-13
TWI771621B (zh) 2022-07-21
CO2021006098A2 (es) 2021-08-09
TWI832295B (zh) 2024-02-11
IL282153B2 (en) 2023-07-01
TW202430498A (zh) 2024-08-01
PH12021550786A1 (en) 2021-10-25
FI3864003T3 (fi) 2023-03-19
HUE061297T2 (hu) 2023-06-28
EP3864003A1 (en) 2021-08-18
DK3864003T3 (da) 2023-03-06
LT3864003T (lt) 2023-03-10
SMT202300058T1 (it) 2023-03-17
BR112021006789A2 (pt) 2021-07-13
ES2938061T3 (es) 2023-04-04
TW202545902A (zh) 2025-12-01
SI3864003T1 (sl) 2023-07-31
JP2025081607A (ja) 2025-05-27
HRP20230222T1 (hr) 2023-09-15
EP4209483B1 (en) 2025-12-03
AR125309A2 (es) 2023-07-05
EP4209483A1 (en) 2023-07-12
CN113423685A (zh) 2021-09-21
UY38415A (es) 2020-04-30
RS64013B1 (sr) 2023-03-31
IL300799B2 (en) 2025-11-01
CN113423685B (zh) 2022-11-29
DOP2021000064A (es) 2021-07-30
IL300799B1 (en) 2025-07-01
US11149043B2 (en) 2021-10-19
US20210230195A1 (en) 2021-07-29
CA3115668A1 (en) 2020-04-16
AU2019356565A1 (en) 2021-05-20
MA53861B1 (fr) 2023-01-31

Similar Documents

Publication Publication Date Title
MX2023009561A (es) Moduladores de profarmacos de la via de estres integrada.
PH12020550523A1 (en) Modulators of the integrated stress pathway
ECSP21086429A (es) Moduladores de la vía integrada del estrés
WO2019090085A8 (en) Modulators of the integrated stress pathway
PH12020550524A1 (en) Modulators of the integrated stress pathway
PH12018502329B1 (en) Modulators of the integrated stress pathway
AU2017261336A1 (en) Modulators of the integrated stress pathway
MX2020004557A (es) Moduladores de la vía de estrés integrada.
AU2017260374A1 (en) Modulators of the integrated stress pathway
MX2020004537A (es) Moduladores de la vía integrada del estrés.
MX2020004538A (es) Moduladores de la vía de estrés integrada.
MX2020004556A (es) Moduladores de la vía de estrés integrada.
UY38685A (es) Moduladores de la vía de tensión integrada
MX2020004534A (es) Moduladores de la vía integrada del estrés.
CR20200213A (es) Moduladores de la vía de estrés integrada
EA202091111A1 (ru) Модуляторы интегрированного стресса